TRIM69

TRIM69 is a RING-domain E3 ubiquitin ligase and interferon-stimulated antiviral effector that acts through two distinct modes—substrate ubiquitination and microtubule-based remodeling—to control viral replication, cell death, and mitotic architecture (PMID:23131556, PMID:36251989). Its RING domain is indispensable for E2-selective ubiquitination activity and also mediates higher-order oligomeric assembly, an unusual property resolved by crystallography to 2.1 Å, that is required both for catalysis and for its non-degradative antiviral function (PMID:23131556, PMID:33021497). As a ligase, TRIM69 directly binds and ubiquitinates diverse substrates with defined linkage specificities: it K48-polyubiquitinates dengue virus NS3 at Lys104 to drive proteasomal degradation and restrict flavivirus replication (PMID:30142214, PMID:35397701), degrades cellular targets including p53, PRKCD (via its B-box domain, K48-linked), and the ferroptosis suppressor FSP1 (PMID:30844644, PMID:37864033, PMID:36423520), and conversely promotes K63-linked ubiquitination of STING to potentiate STING dimerization, TBK1 activation, and type I interferon production (PMID:41865946). In a ubiquitination-independent arm, TRIM69 binds vesicular stomatitis virus phosphoprotein through multimerization to block pioneer viral transcription (PMID:31578292), and engages microtubules directly via a conserved basic surface in its SPRY domain that contacts tubulin C-terminal tails, promoting stable microtubule accumulation that stalls dynein/dynactin motors and inhibits nuclear transport of HIV virion cores, underlying broad restriction of HIV, SIV, VSV, and SARS-CoV-2 (PMID:36251989, PMID:41066114). TRIM69 additionally regulates mitotic fidelity by binding MST2, redistributing it to the perinuclear cytoskeleton and stimulating PLK1-dependent MST2-S15 phosphorylation required for centrosome disjunction, such that its loss causes centrosome scattering and chromosome segregation defects (PMID:37739411).

1. 2003 Medium

   Established TRIM69 (RNF36) as a nuclear-speckle protein that interacts with PML and drives apoptosis, the first hint of its cellular role.

   Evidence Co-immunoprecipitation, immunofluorescence, in vitro phosphorylation, and apoptosis readouts in human cells

   PMID:12837286

   Open questions at the time

   • No enzymatic activity assigned at this stage
   • Functional consequence of PML interaction not mechanistically defined
   • p38 phosphorylation link inferred from inhibitor treatment only
2. 2012 High

   Defined TRIM69 biochemically as a RING-dependent, E2-selective E3 ubiquitin ligase, supplying the catalytic basis for its later substrate-directed functions.

   Evidence In vitro ubiquitination assay with RING mutagenesis plus subcellular imaging

   PMID:23131556

   Open questions at the time

   • No physiological substrate identified
   • E2 partners not enumerated
   • Link between speckled localization and ligase activity unresolved
3. 2016 Medium

   Placed TRIM69 upstream of p53-dependent apoptosis and the AP-1/c-Jun pathway in development, with cross-species rescue confirming functional conservation.

   Evidence Zebrafish morpholino knockdown with human mRNA rescue and c-Jun epistasis

   PMID:27031046 PMID:27050765

   Open questions at the time

   • Direct biochemical link between TRIM69 and tp53/c-Jun in vivo not established
   • Whether regulation is via ubiquitination unaddressed
   • Developmental phenotypes not connected to ligase activity
4. 2018 High

   Identified the first defined viral substrate, showing TRIM69 K48-ubiquitinates dengue NS3 at Lys104 to restrict infection, demonstrating direct antiviral ligase activity.

   Evidence Co-IP, ubiquitination assays, RING and NS3-Lys104 mutagenesis, and a mouse DENV infection model

   PMID:30142214

   Open questions at the time

   • IFN signaling explicitly not modulated, leaving upstream regulation open
   • Breadth across flaviviruses not yet tested
   • Structural basis of NS3 recognition unresolved at this stage
5. 2019 High

   Revealed a ubiquitination-independent antiviral mechanism: TRIM69 multimerizes and binds VSIV phosphoprotein to block pioneer viral transcription rather than degrade it.

   Evidence ISG and loss-of-function screens, Co-IP with VSIV P, viral transcription assays, and multimerization-deficient mutants

   PMID:31375575 PMID:31578292

   Open questions at the time

   • Structural basis of multimerization not yet defined
   • How P sequestration blocks transcription mechanistically unclear
   • Generality of non-degradative mode to other viruses untested
6. 2019 Medium

   Connected TRIM69 to redox and inflammatory signaling by showing p53 ubiquitination (Foxo3a-driven) and ASK1 deubiquitination, expanding its cellular substrate repertoire.

   Evidence Co-IP and ubiquitination/deubiquitination assays plus Trim69 KO mice and epistasis

   PMID:30844644 PMID:31178136

   Open questions at the time

   • A single E3 ligase exhibiting deubiquitination of ASK1 is mechanistically unusual and not reconciled
   • Linkage types and direct vs indirect effects not fully resolved
   • Tissue-specific relevance limited to lens/microglia models
7. 2020 High

   Resolved the structural basis of TRIM69 assembly, showing the RING domain—not the B-box—mediates higher-order oligomerization, rationalizing the multimerization requirement for antiviral activity.

   Evidence SEC-MALLS and 2.1 Å X-ray crystallography of the RING domain

   PMID:33021497

   Open questions at the time

   • Full-length assembly architecture not visualized
   • How oligomerization couples to substrate ubiquitination unresolved
   • Structure does not address microtubule or P-protein binding
8. 2022 High

   Discovered a third mechanism—direct microtubule binding and stabilization—as the basis for TRIM69's broad antiviral restriction in myeloid cells.

   Evidence Direct microtubule binding assays, stable MT quantification, and multiple viral restriction assays (HIV, SIV, VSV, SARS-CoV-2)

   PMID:36251989

   Open questions at the time

   • MT-binding determinant not yet localized to a domain
   • Relationship between MT remodeling and ligase activity unclear
   • How stable MTs restrict diverse viruses not mechanistically defined
9. 2022 High

   Mapped the DENV NS3 interaction interface at molecular resolution and showed flavivirus conservation, generalizing TRIM69's antiviral substrate recognition.

   Evidence HDX-MS interface mapping and ELISA/in vitro ubiquitination of NS2B-NS3Δpro

   PMID:35397701

   Open questions at the time

   • Functional restriction of Zika/WNV/JEV not directly demonstrated
   • Co-crystal structure absent
   • Stoichiometry of ubiquitin transfer unresolved
10. 2022 Medium

    Extended TRIM69's degradative ligase role into cancer cell death control by identifying FSP1 as a substrate whose degradation governs ferroptosis vulnerability.

    Evidence RNA pulldown, Co-IP, ubiquitination assays, and ferroptosis assays with lncFAL competition

    PMID:36423520

    Open questions at the time

    • Ubiquitination linkage type and site on FSP1 not defined
    • Direct vs lncRNA-mediated regulation entangled
    • Single tumor context (HCC)
11. 2023 High

    Defined TRIM69's mitotic function—binding MST2 and stimulating PLK1-dependent S15 phosphorylation for centrosome disjunction—and a B-box-dependent PRKCD-degradation pathway in cancer metastasis.

    Evidence Reciprocal Co-IP, MS, phosphorylation and linkage-specific ubiquitination assays, domain mutants, live imaging, and in vivo metastasis/centrosome readouts

    PMID:37739411 PMID:37864033

    Open questions at the time

    • Whether centrosome role requires ligase activity unclear
    • How MST2 redistribution couples to microtubule binding unresolved
    • Connection between mitotic and antiviral functions not addressed
12. 2025 High

    Pinpointed the SPRY-domain basic surface contacting tubulin C-terminal tails as the molecular basis of microtubule remodeling, mechanistically linking MT stabilization to stalled dynein/dynactin and blocked HIV core nuclear transport.

    Evidence In silico modeling, TIRF microscopy, SPRY mutagenesis, and HIV infection/motor-complex assays; microtubule acetylation shown dispensable by αTAT1 knockout

    PMID:39804091 PMID:41066114

    Open questions at the time

    • Co-structure of SPRY–tubulin not solved
    • How motor stalling is achieved at molecular level incomplete
    • Generality beyond HIV core transport not fully mapped
13. 2026 Medium

    Showed TRIM69 acts as a positive regulator of innate immune signaling by K63-ubiquitinating STING to enhance dimerization and type I IFN output, distinguishing this from its degradative K48 activities.

    Evidence Co-IP, K63-linkage ubiquitination assay, STING dimerization, TBK1 activation, and IFN-I production readouts

    PMID:41865946

    Open questions at the time

    • STING ubiquitination site not mapped
    • Single lab without reciprocal in vivo validation
    • Reconciliation with TRIM69's own ISG-stimulated expression unaddressed

• How TRIM69's three modes—linkage-specific ubiquitination, oligomeric viral-protein sequestration, and SPRY-mediated microtubule remodeling—are coordinated and regulated within a single protein remains unresolved.
• No integrated model linking ligase, multimerization, and MT-binding activities
• Determinants of K48- vs K63-linkage substrate choice unknown
• In vivo importance of mitotic vs antiviral roles not disentangled